Literature DB >> 12067684

Clinical management of dyspnoea.

Jay R Thomas1, Charles F von Gunten.   

Abstract

Dyspnoea, defined as a sensation of an uncomfortable awareness of breathing, is one of the most frightening and distressing symptoms for patients with cancer. It is very common in cancer patients with and without direct lung involvement. The gold standard of diagnosis and assessment is the patient's self-report. Measurements of respiratory rate, oxygen saturation, and arterial blood gases do not measure dyspnoea. Fast, safe, and effective relief of the symptom is possible whether or not identifiable reversible causes exist. Opioids are the first line of therapy for such relief. Medical management can be directed at the underlying cause when the potential benefits outweigh the burdens of such treatment. In rare cases for which symptomatic treatment does not control dyspnoea to the patient's satisfaction, sedation is an effective, ethical option.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067684     DOI: 10.1016/s1470-2045(02)00713-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  17 in total

1.  Killing the symptom without killing the patient.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2010-06       Impact factor: 3.275

2.  Effects of concurrent inspiratory and expiratory muscle training on respiratory and exercise performance in competitive swimmers.

Authors:  Gregory D Wells; Michael Plyley; Scott Thomas; Len Goodman; James Duffin
Journal:  Eur J Appl Physiol       Date:  2005-06-08       Impact factor: 3.078

3.  Application of palliative ventilation: potential and clinical evidence in palliative care.

Authors:  Sebastiano Mercadante; Antonello Giarratano; Andrea Cortegiani; Cesare Gregoretti
Journal:  Support Care Cancer       Date:  2017-04-25       Impact factor: 3.603

Review 4.  Hypnosis for Symptom Control in Cancer Patients at the End-of-Life: A Systematic Review.

Authors:  Guy H Montgomery; Madalina Sucala; Tessa Baum; Julie B Schnur
Journal:  Int J Clin Exp Hypn       Date:  2017 Jul-Sep

5.  Certain bio-psychosocial-spiritual problems associated with dyspnea among advanced cancer patients in Taiwan.

Authors:  Chih-Te Ho; Hua-Shui Hsu; Chia-Ing Li; Chiu-Shong Liu; Chin-Yu Lin; Cheng-Chieh Lin; Wen-Yuan Lin
Journal:  Support Care Cancer       Date:  2011-09-27       Impact factor: 3.603

Review 6.  Symptom burden in heart failure: assessment, impact on outcomes, and management.

Authors:  Craig M Alpert; Michael A Smith; Scott L Hummel; Ellen K Hummel
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

7.  Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101).

Authors:  Kosuke Takahashi; Masashi Kondo; Masahiko Ando; Akira Shiraki; Harunori Nakashima; Hisashi Wakayama; Kensuke Kataoka; Masashi Yamamoto; Yasuteru Sugino; Mitsunori Nishikawa; Kazuyoshi Imaizumi; Eiji Kojima; Atsushi Sumida; Yoshihiro Takeyama; Hiroshi Saito; Yoshinori Hasegawa
Journal:  Oncologist       Date:  2019-01-18

8.  Dyspnoea associated with anxiety--symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  Support Care Cancer       Date:  2010-12-14       Impact factor: 3.603

Review 9.  Pathophysiology and diagnosis of dyspnea in patients with advanced cancer.

Authors:  Gudrun Pohl; Jan Gaertner
Journal:  Wien Med Wochenschr       Date:  2009-12

10.  Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response.

Authors:  Robert B Banzett; Lewis Adams; Carl R O'Donnell; Sean A Gilman; Robert W Lansing; Richard M Schwartzstein
Journal:  Am J Respir Crit Care Med       Date:  2011-07-21       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.